Full Press Release Details
MARINA DEL REY, Calif. , Sept. 21, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx , M.D., Chief Executive Officer, will participate in a panel discussion at the Cantor Global Healthcare Conference, which is being held in New York from September 26-28 , 2023.
Armata's panel discussion is scheduled for Tuesday, September 26 , from 2:45-3:15 PM ET .
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa , Staphylococcus aureus , and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Media Contacts:
At Armata: Pierre Kyme Armata Pharmaceuticals, Inc. [email protected] 310-665-2928
Investor Relations: Joyce Allaire LifeSci Advisors, LLC [email protected] 212-915-2569
SOURCE Armata Pharmaceuticals, Inc.